Review updates clinical management of testicular tumors in dogs: full analysis
Version 2
A newly published review in Animals offers an updated overview of how clinicians should approach testicular tumors in dogs, a common diagnosis in intact male patients that still carries important endocrine and reproductive implications. The paper frames orchiectomy as the mainstay of treatment, while also outlining the narrower situations in which unilateral surgery may be considered if the opposite testis is normal and fertility preservation remains a goal. (mdpi.com)
That message fits with the broader literature. Retrospective studies have consistently found that the dominant canine testicular tumor types are seminomas, Sertoli cell tumors, and interstitial, or Leydig, cell tumors, with affected dogs often presenting in later life. More recent pathology work also suggests that mixed or multiple tumor types in the same testis aren't rare, which can complicate diagnosis and reinforce the value of histopathology after surgery. (pmc.ncbi.nlm.nih.gov)
The review's main clinical contribution is its focus on management rather than pathology alone. According to the article summary, endocrine activity is often more clinically important than malignant behavior. That matters most in Sertoli cell tumors, which are well known for causing hyperestrogenism. Authoritative veterinary references note that hyperestrogenism in these dogs may present with feminization, symmetric alopecia, and, in severe cases, bone marrow suppression. Merck also notes that hyperestrogenism occurs in roughly 25% to 50% of dogs with Sertoli cell tumors, and that other testicular tumors can occasionally produce similar endocrine effects. (merckvetmanual.com)
The paper also appears to bring attention to diagnostic details that may be underused in general practice. Its indexed summary references preputial cytology, serum androgen correlation, and immunohistochemical markers such as PLAP, c-Kit, and OCT3/4 in tumor classification. That's notable because these cases can be diagnostically messy, especially in cryptorchid dogs or in dogs with endocrine signs but no clearly palpable scrotal mass. Cornell's recent client education material similarly stresses that retained testicles increase the risk of neoplasia and that hormone testing can help confirm residual testicular tissue when exam findings are unclear. (mdpi.com)
Direct outside commentary on this specific review was limited in the sources available during reporting, but the wider veterinary literature strongly supports its practical conclusions. WSAVA's 2024 reproduction guidelines state that gonadectomy prevents testicular diseases including tumors, while educational oncology material from MSPCA notes that paraneoplastic hyperestrogenism, contralateral testicular atrophy, and cryptorchid status all shape case presentation and clinical suspicion. Taken together, the industry view is less about a change in standard of care than a clearer synthesis of when endocrine workup and individualized surgical planning matter most. (wsava.org)
Why it matters: For practicing veterinarians, this review is a timely consolidation of a condition that is common, usually treatable, but sometimes more systemically important than it first appears. The biggest takeaway is that successful management depends on recognizing when a testicular tumor is functioning hormonally, not just identifying its histologic subtype. In referral and reproductive practice, the discussion of unilateral orchiectomy may also be relevant for carefully selected breeding or working dogs, though the default approach remains removal of the affected testicle, and often castration, with histopathology guiding follow-up. (mdpi.com)
What to watch: The next question is whether this review meaningfully shifts frontline workups, particularly around endocrine screening, cryptorchid case detection, and criteria for unilateral versus bilateral surgery in dogs where fertility is still under consideration. (mdpi.com)